Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tagraxofusp Clear all
Completed Phase 1Phase 2 Interventional Results available

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

NCT02113982
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML)
Interventions
Tagraxofusp
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Duarte, California • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 3, 2026, 4:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

NCT06561152
View directory record Official record
Conditions
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
Interventions
Tagraxofusp, Cladribine (CLAD), Cytarabine
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Recruiting Phase 2 Interventional

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

NCT05442216
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp, Azacitidine, Venetoclax
Drug
Lead sponsor
Joshua Zeidner
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
7
States / cities
Miami, Florida • Orlando, Florida • Buffalo, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

NCT03113643
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Azacitidine, SL-401, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT05032183
View directory record Official record
Conditions
Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Lymphoblastic Lymphoma, Refractory T Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Filgrastim-sndz, Leucovorin, Mercaptopurine, Mesna, Methotrexate, Pegfilgrastim, Prednisone, Rituximab, Tagraxofusp-erzs, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 3, 2026, 4:21 AM EDT
Recruiting Phase 2 Interventional

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT04216524
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Mercaptopurine, Methotrexate, Methylprednisolone, Prednisone, Rituximab, Tagraxofusp-erzs, Venetoclax, Vincristine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

NCT07148180
View directory record Official record
Conditions
Acute Myeloid Leukaemia (AML), Leukemia, Blood Cancer, Blood Cancers
Interventions
Tagraxofusp, Azacitidine (AZA), Venetoclax
Drug
Lead sponsor
Jacqueline Garcia, MD
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Terminated Phase 1 Interventional

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

NCT05716009
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Withdrawn Phase 1 Interventional

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

NCT05720988
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Tagraxofusp-erzs
Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 3, 2026, 4:21 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

NCT05233618
View directory record Official record
Conditions
Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
Tagraxofusp
Drug
Lead sponsor
Karen Ballen, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

NCT02268253
View directory record Official record
Conditions
Myelofibrosis, Chronic Myelomonocytic Leukemia
Interventions
Tagraxofusp Injection
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
22
States / cities
Clovis, California • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Sep 3, 2026, 4:21 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

NCT05038592
View directory record Official record
Conditions
Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
Decitabine, Tagraxofusp-erzs
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

NCT06498973
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Questionnaire Administration, Tagraxofusp-erzs
Drug · Procedure · Other + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

NCT02270463
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp-erzs
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
7
States / cities
Tampa, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 3, 2026, 4:21 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

NCT03386513
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
Interventions
IMGN632
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
15
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 3, 2026, 4:21 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

NCT06414681
View directory record Official record
Conditions
Myelofibrosis，MF
Interventions
Tagraxofusp, Pacritinib
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 3, 2026, 4:21 AM EDT
Terminated Phase 2 Interventional Results available

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

NCT04317781
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Tagraxofusp-erzs
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 3, 2026, 4:21 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

NCT02661022
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SL-401 7 µg/kg/day, SL-401 9 µg/kg/day
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Duarte, California • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Sep 3, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

NCT05476770
View directory record Official record
Conditions
Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Interventions
Tagraxofusp, Fludarabine, Cytarabine, Dexamethasone, Vincristine, Azacitidine, Methotrexate, Cytarabine IT, Hydrocortisone
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
29
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 3, 2026, 4:21 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

NCT06456463
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp, Venetoclax, Azacitidine
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
24
States / cities
Los Angeles, California • Stanford, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 3, 2026, 4:21 AM EDT